Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer.

MLA

Wang, Jia-Bin, et al. “Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer.” Advanced Science (Weinheim, Baden-Wurttemberg, Germany), vol. 10, no. 15, May 2023, p. e2207417. EBSCOhost, https://doi.org/10.1002/advs.202207417.

APA

Wang, J.-B., Qiu, Q.-Z., Zheng, Q.-L., Zhao, Y.-J., Xu, Y., Zhang, T., Wang, S.-H., Wang, Q., Jin, Q.-W., Ye, Y.-H., Li, P., Xie, J.-W., Lin, J.-X., Lu, J., Chen, Q.-Y., Cao, L.-L., Yang, Y.-H., Zheng, C.-H., & Huang, C.-M. (2023). Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 10(15), e2207417. https://doi.org/10.1002/advs.202207417

Chicago

Wang, Jia-Bin, Qing-Zhu Qiu, Qiao-Ling Zheng, Ya-Jun Zhao, Yu Xu, Tao Zhang, Shuan-Hu Wang, et al. 2023. “Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer.” Advanced Science (Weinheim, Baden-Wurttemberg, Germany) 10 (15): e2207417. doi:10.1002/advs.202207417.